UBS upgrades Big Pharma stock after shares drop on poor drug results
The Swiss bank believes the pharmaceutical giant's 30-drug-trial pipeline makes it a "leading player in this field" and expects shares to rise by nearly 30%.
Source link
The Swiss bank believes the pharmaceutical giant's 30-drug-trial pipeline makes it a "leading player in this field" and expects shares to rise by nearly 30%.
Source link
